Oncology Peer Review On-The-Go: Examining Evidence Underlying the NCCN Guidelines for Hematologic Malignancies

Article

On this CancerNetwork® podcast, we examine the scientific evidence behind the National Comprehensive Cancer Network guidelines for hematologic malignancies.

This week, the CancerNetwork® editors review a manuscript published in the July issue of the journal ONCOLOGY® titled, “Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies.” Corresponding author Thejaswi K. Poonacha, MD, MBA, a staff physician and hospitalist in the Department of Internal Medicine at the University of Minnesota Medical Center, joined the show to discuss the conclusions of his colleagues.

The conversation focused on the scientific evidence behind the National Comprehensive Cancer Network guidelines for hematologic malignancies, the different levels of evidence supporting the recommendations, and the main conclusions of the research. Poonacha also shared why he thinks this research is significant for the authors as well as physicians treating patients with hematologic malignancies nationwide.



Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.